August 20, 2021
Bristol-Myers unit Celgene has reached a settlement with India-based Hetero Labs, marking the final settlement to come out of Celgene's 2017 lawsuit against a raft of generic-drug makers over patents for its blockbuster cancer medication Pomalyst, according to a consent judgment approved Thursday in New Jersey federal court.
March 02, 2018
A New Jersey federal judge on Friday refused to dismiss Mylan NV from a suit Celgene Corp. brought against the pharmaceutical company and others to block generic versions of its skin cancer treatment, giving Celgene time to investigate whether Mylan has an established business in the Garden State.